A Food and Drug Administration advisory committee was scheduledto meet Dec. 11 to discuss ATL's premarket approval (PMA) applicationfor using ultrasound to differentiate benign from malignant breastlesions. If the PMA is approved, it could represent a
A Food and Drug Administration advisory committee was scheduledto meet Dec. 11 to discuss ATL's premarket approval (PMA) applicationfor using ultrasound to differentiate benign from malignant breastlesions.
If the PMA is approved, it could represent a major step inthe expansion of ultrasound in breast imaging. ATL hopes thatthe use of its HDI technology for differentiating breast ultrasoundlesions could reduce the need for breast biopsy by 35%.
ATL, of Bothell, WA, filed the PMA in February 1994 (SCAN 1/19/94).The application received fast-track review status from the FDA,leading the company to hope that it would be approved that year.The filing has languished at the agency since then, however.
At Monday's meeting, the FDA committee was scheduled to discussthe PMA and recommend whether the agency should approve it. TheFDA typically acts on advisory committee approval recommendationswithin several months after they are issued.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.